Skip to content
  • (312) 598-2610
  • info@ipfdalaw.com
  • 109 Symonds Drive, #174, Hinsdale, IL 60522-0174
Search
Close
Untitled design (7)
  • About
    • Detailed Description
    • Our Team
    • Fee Structures
  • Services
    • Patent Litigation
    • Commercial Litigation
    • False Advertising & Unfair Competition
    • Generic Drugs
    • Branded Drugs and 505(b)(2)
    • Medical Devices
    • FDA/Exclusivity/GMP
    • Contracts & Licensing
    • Government Investigations
  • News
  • Videos
  • Recent Cases
  • Contact Us
Menu
  • About
    • Detailed Description
    • Our Team
    • Fee Structures
  • Services
    • Patent Litigation
    • Commercial Litigation
    • False Advertising & Unfair Competition
    • Generic Drugs
    • Branded Drugs and 505(b)(2)
    • Medical Devices
    • FDA/Exclusivity/GMP
    • Contracts & Licensing
    • Government Investigations
  • News
  • Videos
  • Recent Cases
  • Contact Us
More Information

Day: December 20, 2022

Five (5) & Ten (10) Year Data Exclusivity for New Drugs – When To File Generic Drug Applications

Brand pharma companies invest valuable resources, time, and money in moving drugs from development to FDA approval. The new drug approval may also enjoy some type of FDA exclusivity. Typically, FDA exclusivity falls into two types: (1) data exclusivity; and (2) approval/market exclusivity, both of which are known in the industry but not defined expressly […]

Patents
Hatch-Waxman Litigation
Trade Secrets
Antitrust/Unfair Competition
FDA Counseling
Branded/Generic/ 505(b)(2)
Life Cycles
Contracts Licensing
Freedom to Operate

Quick Contact

Address

  • 109 Symonds Drive, #174, Hinsdale, IL 60522-0174
  • (312) 598-2610
  • info@ipfdalaw.com

Ⓒ 2021 - IPFDA law All Rights Are Reserved